Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 100% Improvement Relative Risk Hospitalization 100% Mortality (b) 97% Hospitalization (b) 99% c19hcq.org Tyson et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+multiple treatments beneficial for COVID-19? Retrospective 25,296 patients in the USA Lower mortality (p<0.0001) and hospitalization (p<0.0001) Tyson et al., Preprint Favors HCQ Favors control
Low Rates of Hospitalization and Death in 4,376 COVID-19 Patients Given Early Ambulatory Medical and Supportive Care. A Case Series and Observational Study.
Tyson et al., Preprint (Preprint)
Tyson et al., Low Rates of Hospitalization and Death in 4,376 COVID-19 Patients Given Early Ambulatory Medical and.., Preprint (Preprint)
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 4,376 patients with mild/moderate COVID-19 in the USA treated with multiple medications including HCQ/ivermectin, favipiravir, vitamin C, D, quercetin, zinc, mAbs, budesonide, dexamethasone, prednisone, and colchicine (exact treatments specific to each patient), showing significantly lower hospitalization and mortality compared to the surrounding community.
risk of death, 99.8% lower, RR 0.002, p < 0.001, treatment 0 of 3,962 (0.0%), control 471 of 20,921 (2.3%), NNT 44, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), All AVUC mild patients vs. Imperial County (corrected).
risk of hospitalization, 99.8% lower, RR 0.002, p < 0.001, treatment 2 of 3,962 (0.1%), control 4,343 of 20,921 (20.8%), NNT 4.8, All AVUC mild patients vs. Imperial County (corrected).
risk of death, 97.0% lower, RR 0.03, p < 0.001, treatment 3 of 4,375 (0.1%), control 471 of 20,921 (2.3%), NNT 46, All AVUC patients vs. Imperial County (corrected).
risk of hospitalization, 99.0% lower, RR 0.010, p < 0.001, treatment 9 of 4,375 (0.2%), control 4,343 of 20,921 (20.8%), NNT 4.9, All AVUC patients vs. Imperial County (corrected).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tyson et al., 13 Jan 2022, retrospective, USA, preprint, 13 authors, this trial uses multiple treatments in the treatment arm (combined with multiple treatments) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit